ERBB2 and gastric cancer: Although the development of molecular targeted therapies, such as human epidermal growth factor receptor 2 (HER2) monoclonal antibody, improves the prognosis of advanced gastric cancer, the applicable population is narrow, facing the problem of drug resistance (6–8).